Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Goodbye Needles, Hello Convenience: Exploring Compounded Semaglutide

By: NewsUSA

(Madison Roberts) - A Convenient New Approach to Metabolic Health

Eden is providing access to a new way for individuals to explore GLP-1 therapy: a compounded semaglutide gummy, available through independent licensed providers and compounding pharmacies. Compounded semaglutide is available in different forms, including injections and gummies. Some patients may prefer alternative formats, but efficacy and safety data are limited. While compounded semaglutide is commonly prescribed in injectable form, this tropical-flavored gummy offers an alternative format that some patients may prefer, which independent licensed providers can discuss as a potential option.

Meeting Patients Where They Are
Many Americans face challenges related to metabolic health, including obesity and its associated conditions. Barriers such as needle anxiety or complex treatment regimens often prevent individuals from seeking care. Eden aims to make it easier for patients to connect with independent licensed doctors who can evaluate their health needs and discuss potential treatment options. 

"Adherence improves when treatment integrates easily into patients’ lives," explains Adam McBride, Eden’s CEO. Eden’s digital platform streamlines access to independent healthcare professionals who can assess patients and determine eligibility for treatments like GLP-1 receptor agonists, including compounded semaglutide. 

Understanding GLP-1 Therapy
GLP-1 receptor agonists, such as semaglutide, are FDA-approved for managing type 2 diabetes and  weight management when combined with diet and exercise. Some studies suggest these medications may influence appetite and blood sugar levels. 

Affordable and Accessible Care
Eden connects patients with independent licensed healthcare providers for digital consultations, personalized care plans, and resources such as on-demand workout videos—all for $246 per month. This model aims to eliminate barriers to care by meeting patients’ needs through a convenient, fully digital platform.

Reframing the Conversation Around Metabolic Health
Eden’s goal is to support individuals on their journey toward sustainable health improvements by connecting them with personalized care options. Rather than focusing on quick fixes, Eden emphasizes long-term, personalized care that empowers patients to feel their best.

"We’re shifting the conversation to focus on sustainable and manageable health goals," says Eden President Josh Khan. "By making care more accessible, we hope to break down barriers and make a real impact on patients’ lives."

The Future of GLP-1 Treatments
Emerging research suggests that GLP-1 therapies may play a role in broader aspects of metabolic health. While studies explore potential applications in areas such as non-alcoholic fatty liver disease and inflammatory conditions. Patients are encouraged to consult with an Eden network provider to discuss potential benefits and determine what therapies are appropriate for their individual needs.

A Healthier Future, One Step at a Time
Eden’s mission is simple: to make access to care seamless and empowering. Through their digital platform, Eden connects patients with licensed medical professionals who provide guidance informed by the latest scientific evidence. 

Important Note:
Compounded semaglutide is not FDA-approved for safety or efficacy. All treatment plans and prescriptions are determined solely by the independent licensed healthcare providers patients consult through the Eden platform. While Eden does not manufacture or compound medications, it serves as a trusted resource connecting patients with qualified providers to explore treatment options. By simplifying access to care, Eden helps patients connect with providers as they take the first step toward addressing their metabolic health needs. 

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.